number of antibiotics are available for the treatment of MRSA pneumonia, including vancomycin, clindamycin, and linezolid. 2 The use of linezolid is continuously increasing because of the development of resistant strains of bacteria, particularly in ICUs where this antibiotic plays an important role in the treatment of multidrug-resistant gram-positive nosocomial pneumonia, especially when other antimicrobial therapies fail. 2 Linezolid has excellent tissue penetration, and it lacks cross-resistance with current antibiotic therapies because of its unique mechanism of action. 3 In addition, its dosage does not typically have to be adjusted in patients with impaired renal function. 4 Although generally considered safe, linezolid was associated with adverse haematological reactions such as thrombocytopenia and anaemia in approximately 2.4% of patients in a phase III trial. 5 Two previous studies reported incidence rates of 3.3% 6 and 6.4% 7 for
linezolid-induced thrombocytopenia in inpatient setting and orthopaedic population, respectively. In addition, a higher incidence of severe thrombocytopenia was reported in patients with end-stage renal disease. 8, 9 Since the presence of various confounding conditions ICU patients, 10 ,11 these previous evaluations have been limited to patients in non-ICU settings. Moreover, there are no studies on the relationship between linezolid-induced thrombocytopenia and mortality in the ICU, yet, especially with low incidence of linezolid-induced thrombocytopenia. Therefore, in this study, we investigated the incidence, risk factors and outcomes for linezolid-induced thrombocytopenia in patients who underwent linezolid therapy in the ICU during 10 years. causes of thrombocytopenia, the Naranjo algorithm was used on a case-by-case basis according to published criteria to determine the degree of probability that the thrombocytopenia was induced by linezolid as either definite, probable, possible, or unlikely. 
| ME THODS
This
| Data collection
The following data were collected from patient electronic medical records: age, gender, comorbidities, source of infection, microbial organism, duration of mechanical ventilation, transfusion requirements, length of ICU stay, and ICU mortality. The following laboratory values were collected for all patients when available: haemoglobin, serum creatinine, albumin, total bilirubin, and white blood cell and platelet counts.
We also noted whether the patients received drugs that are commonly implicated in thrombocytopenia such as heparin products (ie, unfractionated and low-molecular weight heparins). 14 
| RE SULTS
The demographics and clinical characteristics of the study population are displayed in Table 1 . Of the total 88 patients screened, 60 patients (45 males, mean age of 69.8 ± 11.9 years) were included in the study. The mean duration of linezolid therapy was 11.5 ± 5.0 days. Of the 29 cases of thrombocytopenia, 37.9% (n = 11) were resolved by discontinuation of linezolid. Severe thrombocytopenia
/L) developed in 20.7% (n = 6). The degree of probability for each case of linezolid-induced thrombocytopenia was calculated using the Naranjo algorithm, and these values are listed in Table 2 .
Patients who developed thrombocytopenia received significantly more platelet transfusions (34.5% vs 6.5% of cases, were significant risk factors for the development of linezolid-induced thrombocytopenia in the ICU (Table 4) .
| D ISCUSS I ON
It is important to identify the factors associated with linezolid-induced thrombocytopenia because the development of thrombocytopenia necessitates the discontinuation of linezolid administration, which is a notable treatment interruption.
Furthermore, thrombocytopenia has been reported to be strongly associated with poor outcomes, including the development of /L, and a decrease in at least 50% from baseline. b Antibacterial agents, chemo agents, acetaminophen, carbamazepine, enoxaparin, ranitidine.
TA B L E 1 (Continued)
F I G U R E 1 Platelet counts according to days of linezolid administration. ---No thrombocytopenia, ----Linezolidinduced thrombocytopenia. *The median platelet count in the linezolid-induced thrombocytopenia group was significantly lower than that in the patients without thrombocytopenia (P < 0.05). LIT, linezolid-induced thrombocytopenia organ failure and increases in hospitalization duration and mortality, it is critical to determine the incidence and risk factors of linezolid-induced thrombocytopenia in hospitalized patients. 10, 15, 16 The reported risk factors associated with linezolid-induced thrombocytopenia include prolonged treatment, renal insufficiency, chronic liver disease, and increased trough plasma linezolid concentration. 5 However, few studies have evaluated the prognostic importance of linezolid-induced thrombocytopenia targeting ICU patients population. One of the challenges associated with such studies is the presence of various confounding conditions ICU patients, such as illness severity (as suggested by high acute physiology and chronic health evaluation; APACHE II, sepsis-related organ failure assessment; SOFA, and simplified acute physiology score; SAPS), sepsis, invasive vascular catheters, severe malnutrition, disseminated intravascular coagulation, heparin administration, and low baseline platelet level upon admission to the ICU. 10, 11 In addition to confounding conditions, the number of incidence of linezolid-induced thrombocytopenia with critically ill patients may be underreported or have not enough power to analyze with significant outcomes like mortality. However, considering the importance of such a study in ICU patients, we analysed the incidence of linezolid-induced thrombocytopenia as well as factors associated with this condition in critically ill patients. The incidence of thrombocytopenia in our study patients was 48.3%, which was high and inconsistent with the incidence rates reported previously by Takahashi et al (38.7%) 17 and Chen et al (27.2%). 18 These discrepancies could be due to differences in the study populations, as our study included only ICU patients and the previous studies included patients in the general ward.
In the present study, the presence of any malignancy and an insufficiency in adults; however, our findings conflict with these practices. We found that a baseline serum creatinine of ≥1.5 mg/dL was associated a significantly higher incidence of linezolid-induced thrombocytopenia. Additionally, Nukui et al 20 reported that patients with renal insufficiency were likely to have high plasma linezolid concentrations. Therefore, linezolid dose adjustment would decrease the adverse effect and should be considered or at least closely monitored for ICU patients with renal insufficiency.
TA B L E 3 Clinical outcome data for patients
We also conducted a time-to-event analysis of the incidence of thrombocytopenia. As the rough look of the disease severity in critically ill patients can be evaluated clinically with scoring system, we assessed whether higher APACHE II, SOFA, and SAPS II scores were potential risk factors for linezolid-induced thrombocytopenia. No significant correlation was found between the SOFA and SAPS severity scores and the risk of thrombocytopenia. However, the mean APACHE II score tended to be higher in patients who developed linezolid-induced thrombocytopenia, with the prevalence of linezolid-induced thrombocytopenia being significantly higher in patients with an APACHE II score ≥25 than in patients with an APACHE II score <25. A previous study revealed that illness severity and APACHE II scores are independent risk factors for linezolid-induced thrombocytopenia. 21 The patients enrolled in the present study were critically ill ICU patients with high APACHE II scores, which may have increased the incidence of linezolid-induced thrombocytopenia. To the best of our knowledge, this is the first report to elucidate the relationship between SOFA and SAPS scores, in addition to APACHE II score, and the risk of thrombocytopenia.
Zhang et al 1 reported that, among patients aged ≥65 years, the cumulative incidence of thrombocytopenia in patients receiving linezolid was significantly higher than that in patients receiving glycopeptide antibiotics. Furthermore, in our study, the median platelet count on day 6 of linezolid treatment was significantly lower in the thrombocytopenia group even though 34.5% of patients who developed thrombocytopenia received a transfusion of platelet products.
In our study, 20.7% were categorized as having a severe linezolid-induced thrombocytopenia in the present study, whereas Patel et al 6 reported an incidence of only 3.6% for severe linezolid-induced thrombocytopenia. The inconsistency between our results and those of previous studies could be because our study was conducted in an ICU setting, where the severity of thrombocytopenia is anticipated to be higher. Analysis using the Naranjo algorithm revealed a 75.9% probability of linezolid being the cause of thrombocytopenia, which was similar to that described by Poulakos et al. 13, 22 Additionally, the thrombocytopenia group had significantly higher ICU mortality and tended to have a longer duration of stay in the ICU. In addition, our study has shown that, in 37.9% of cases, linezolid-induced thrombocytopenia resolved by discontinuation of linezolid. Thus, in these critically ill patients with impaired renal function or any other malignancy disease, clinicians should consider the options of other antimicrobial agents in order to improve the quality of medical treatment by preventing linezolid-induced thrombocytopenia.
Our results indicate that further research such as pharmacokinetic analysis of linezolid should be conducted to determine if the incidence of linezolid-induced thrombocytopenia in critically ill patients could be reduced via dose adjustment according to serum linezolid concentration.
Some limitations should be noted when interpreting these results. Since this was a retrospective study, we could not control for all confounding factors that could have been present in these critically ill patients. Secondly, since linezolid-induced thrombocytopenia was rare incidence and we only included the ICU population, the number of study patients was small. However, we believe that our results would be convinced since this kind of study could be hard by a prospective or a national claims data analysis.
Moreover, the pertinent patient demographic information from both groups was similar. Lastly, because plasma linezolid concentrations were not documented for all patients, we could not investigate whether thrombocytopenia was caused by variations in linezolid pharmacokinetics.
| WHAT IS NE W AND CON CLUS I ON S
The present study evaluated the risk factors for linezolid-induced thrombocytopenia in ICU patients. ICU patients with any malignancy or an elevated baseline serum creatinine, especially with creatinine ≥1.5 mg/dL, were more likely to develop linezolid-induced thrombocytopenia. These data suggest that linezolid should be used more carefully in ICU patients with any malignancy or an elevated baseline creatinine and it warrants the prospective study to confirm in near future.
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